Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Microbiology

Comparison of antimicrobial susceptibility testing methods for aztreonam-avibactam against NDM-producing Enterobacterales clinical isolates

3 more authors
10 affiliations
  1. 1Genomics & Resistant Microbes Group (GeRM), Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile
  2. 2Multidisciplinary Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago, Chile
  3. 3Surveillance, Epidemiology, and New Technologies for Infectious Emerging Threats (SENTINET), Santiago, Chile
  4. 4UC Irvine School of Medicine, Irvine, California, USA
  5. 5Hospital Padre Hurtado, Santiago, Chile
  6. 6Pontificia Universidad Católica de Chile, Santiago, Chile
  7. 7Hospital La Florida, Santiago, Chile
  8. 8Hospital Regional de Puerto Montt, Universidad San Sebastián, Puerto Montt, Chile
  9. 9Hospital Dipreca, Santiago, Chile
  10. 10The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Abstract

Aztreonam-avibactam (ATM-AVI) is a promising therapeutic for New Delhi metallo-β-lactamase-producing Enterobacterales (NDM-E) infections. We evaluated the performance of disk diffusion and gradient diffusion methods compared with reference broth microdilution (BMD) for ATM-AVI susceptibility testing. A total of 245 non-duplicate NDM-E isolates were included, collected from unique patients at hospitals in Chile and the United States between 2022 and 2024. Nine ATM-AVI non-susceptible isolates from a separate collection were added to enrich for resistant isolates, yielding a total of 254 isolates. Reference BMD was performed according to Clinical and Laboratory Standards Institute (CLSI) criteria. ATM-AVI disk diffusion and two gradient diffusion methods (ETEST and MIC Test Strip) were evaluated against BMD using categorical agreement, essential agreement, and CLSI-defined error rates. All 245 NDM-E isolates were susceptible to ATM-AVI (MIC ≤4/4 µg/mL), with MIC₅₀/₉₀ values of 0.25/4 and 1/4 µg/mL, respectively. The collection consisted of Klebsiella pneumoniae (71%), Enterobacter cloacae complex (21%), and Escherichia coli (8%). Predominant NDM alleles included blaNDM-1 and blaNDM-7. Disk diffusion demonstrated 98% categorical agreement (250/254), with four minor errors. Both gradient diffusion methods achieved 99% categorical agreement (252/254), with no very major or major errors and two minor errors. Essential agreement was 67% for ETEST and 85% for MIC Test Strip; both methods tended to underestimate ATM-AVI MICs relative to BMD. ATM-AVI demonstrated robust in vitro activity against a contemporary NDM-E cohort. Disk and gradient diffusion methods are practical alternatives to BMD for clinical laboratories.

Related

  1. Activity of aztreonam–avibactam and comparators against difficult-to-treat resistant Enterobacterales from United States medical centres (2020–24) †
    Helio S Sader, John H Kimbrough, Dmitri Debabov +2
    JAC-Antimicrobial ResistancePeer-reviewedCC BY 4.0Full textInfectious diseasePMC
  2. Longitudinal Multicenter Susceptibility Trends of Ceftazidime/Avibactam and Imipenem/Relebactam and Dose Optimization in Critically Ill Patients with Carbapenem-Resistant Enterobacterales Bloodstream Infections
    Xueting Wang, Pan Chen, Tao Chen +8
    Drug Design, Development and TherapyPeer-reviewedCC BY-NCFull textPharmacology & toxicologyDOAJEurope PMCPMC
  3. From sepsis to necrotizing enterocolitis with appendiceal perforation: a case report of successful salvage therapy with aztreonam–avibactam in an extremely preterm infant with NDM-producing Klebsiella pneumoniae
    Yang He, Jichong Huang, Bin Du +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMCPMCEurope PMC
  4. Successful treatment of NDM-type carbapenemase-producing CRKP bacteremia and intra-abdominal infection in severe acute pancreatitis with aztreonam-avibactam: a case report
    Zhiyang Wu, Juan Zhang, Yingjie Wang +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  5. In Vitro Activity of Eravacycline, Aztreonam-Avibactam, and Cefiderocol Against Multidrug-Resistant Gram-Negative Clinical Isolates from a Romanian Tertiary Hospital.
    Anda Baicus, Valentina Daniela Sisu, Andreia Domnica Tatar +4
    Antibiotics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{rivas2026comparison,
  title = {{Comparison of antimicrobial susceptibility testing methods for aztreonam-avibactam against NDM-producing Enterobacterales clinical isolates}},
  author = {Lina Rivas and Lorena Díaz and Valeria Quiroz and Jose R. W. Martinez and Camila Solar and Ayesha Khan and Katherine Soto and Pamela Rojas Soto and Maria-Paz Acuña and María L. Rioseco and Margareta Mühlhauser and Yehudit Bergman and Patricia García and José M. Munita and Pranita D. Tamma},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  month = oct,
  doi = {10.1128/jcm.00797-26},
  url = {https://doi.org/10.1128/jcm.00797-26},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Comparison of antimicrobial susceptibility testing methods for aztreonam-avibactam against NDM-producing Enterobacterales clinical isolates
AU  - Lina Rivas
AU  - Lorena Díaz
AU  - Valeria Quiroz
AU  - Jose R. W. Martinez
AU  - Camila Solar
AU  - Ayesha Khan
AU  - Katherine Soto
AU  - Pamela Rojas Soto
AU  - Maria-Paz Acuña
AU  - María L. Rioseco
AU  - Margareta Mühlhauser
AU  - Yehudit Bergman
AU  - Patricia García
AU  - José M. Munita
AU  - Pranita D. Tamma
PY  - 2026
DA  - 2026/10/12
JO  - Journal of Clinical Microbiology
DO  - 10.1128/jcm.00797-26
UR  - https://doi.org/10.1128/jcm.00797-26
AB  - Aztreonam-avibactam (ATM-AVI) is a promising therapeutic for New Delhi metallo-β-lactamase-producing Enterobacterales (NDM-E) infections. We evaluated the performance of disk diffusion and gradient diffusion methods compared with reference broth microdilution (BMD) for ATM-AVI susceptibility testing. A total of 245 non-duplicate NDM-E isolates were included, collected from unique patients at hospitals in Chile and the United States between 2022 and 2024. Nine ATM-AVI non-susceptible isolates from a separate collection were added to enrich for resistant isolates, yielding a total of 254 isolates. Reference BMD was performed according to Clinical and Laboratory Standards Institute (CLSI) criteria. ATM-AVI disk diffusion and two gradient diffusion methods (ETEST and MIC Test Strip) were evaluated against BMD using categorical agreement, essential agreement, and CLSI-defined error rates. All 245 NDM-E isolates were susceptible to ATM-AVI (MIC ≤4/4 µg/mL), with MIC₅₀/₉₀ values of 0.25/4 and 1/4 µg/mL, respectively. The collection consisted of Klebsiella pneumoniae (71%), Enterobacter cloacae complex (21%), and Escherichia coli (8%). Predominant NDM alleles included blaNDM-1 and blaNDM-7. Disk diffusion demonstrated 98% categorical agreement (250/254), with four minor errors. Both gradient diffusion methods achieved 99% categorical agreement (252/254), with no very major or major errors and two minor errors. Essential agreement was 67% for ETEST and 85% for MIC Test Strip; both methods tended to underestimate ATM-AVI MICs relative to BMD. ATM-AVI demonstrated robust in vitro activity against a contemporary NDM-E cohort. Disk and gradient diffusion methods are practical alternatives to BMD for clinical laboratories.
SN  - 0095-1137
SN  - 1098-660X
ER  -